

(43) International Publication Date
23 December 2010 (23.12.2010)(10) International Publication Number
WO 2010/146488 A1

(51) International Patent Classification:

C07D 215/60 (2006.01) **C07D 491/04** (2006.01)
C07D 401/04 (2006.01) **A61K 31/4375** (2006.01)
C07D 401/12 (2006.01) **A61K 31/4704** (2006.01)
C07D 405/04 (2006.01) **A61P 25/00** (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:

PCT/IB2010/052349

(22) International Filing Date:

26 May 2010 (26.05.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/218,149 18 June 2009 (18.06.2009) US
 61/334,389 13 May 2010 (13.05.2010) US

(71) Applicant (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and



(75) Inventors/Applicants (for US only): **CLAFFEY, Michelle Marie** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **DOUNAY, Amy Beth** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **GAN, Xinmin** [CN/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **HAYWARD, Matthew Merrill** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **RONG, Suobao** [CN/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **TUTTLE, Jamison Bryce** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **VERHOEST, Patrick Robert** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US).

(74) Agent: **KLEIMAN, Gabriel L.**; Pfizer Inc. 235 East 42 Street, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

[Continued on next page]

(54) Title: BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS

FIG. 1

(57) Abstract: Compounds of Formula X: wherein A, X, Y, Z, R⁵, R^{5a}, and R^{5b} are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.



AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))